GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GT Biopharma Inc.
GT Biopharma is a biotech company developing cancer immunotherapy drugs. Its stock price represents a venture bet on its scientific platform, TriKE. The chart reflects the high volatility associated with clinical trial news.
Share prices of companies in the market segment - Cancer blood
GT Biopharma is developing the TriKE immunotherapeutic platform for activating natural killer cells (NK cells) to combat blood cancers and solid tumors. We've categorized it under "Blood Cancer." The chart below shows how the market is valuing this leading immuno-oncology sector.
Broad Market Index - GURU.Markets
GT Biopharma is an oncology company developing the TriKE immunotherapy platform for activating natural killer (NK) cells. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
GTBP - Daily change in the company's share price GT Biopharma Inc.
For GT Biopharma, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Cancer blood
GT Biopharma develops innovative NK cell-based immunotherapy for cancer treatment. The cell therapy sector is one of the most advanced and volatile in biotech. The chart below shows the average daily fluctuations in this industry, serving as a benchmark for evaluating the highly volatile GTBP stock.
Daily change in the price of a broad market stock, index - GURU.Markets
GT Biopharma is a biotech company developing cell therapy for blood cancer. Its shares are a bet on a scientific breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GT Biopharma Inc.
GT Biopharma, Inc.'s year-over-year performance is the story of its TriKE® cell therapy platform. Its 12-month market cap is entirely dependent on clinical trial data. The success of its approach, which directs NK cells to destroy cancer cells, could be a breakthrough in the treatment of blood cancers.
Annual dynamics of market capitalization of the market segment - Cancer blood
As an early-stage biotech company, GT is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cell therapy. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GT Biopharma is an immuno-oncology company whose stock is betting on a new generation of cell therapy. Its performance is completely disconnected from the market and is determined by news of clinical successes or failures of its TriKE platform. It's a high-risk play, where scientific data can change everything overnight.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GT Biopharma Inc.
GT Biopharma is an immuno-oncology company. Its monthly performance is driven by progress in clinical trials of its TriKE platform. Positive data from its programs, presented at conferences, is the main driver of its valuation.
Monthly dynamics of market capitalization of the market segment - Cancer blood
Cancer immunotherapy using NK cells is one of the most cutting-edge areas. The dynamics of this biotech sector, shown in the chart, reflect investors' faith in this technology. Companies like GT Biopharma are developing their platform in this area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GT Biopharma, a biopharmaceutical company focused on immuno-oncology, thrives in a world of clinical data. Its shares rise and fall on trial news, defying overall market trends. This chart demonstrates this independence.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GT Biopharma Inc.
Shares of GT Biopharma, a cancer immunotherapy company, are extremely volatile. Weekly price movements depend entirely on news about the clinical trials of their TriKE platform. The chart below illustrates how short-term scientific developments and investor hopes for a breakthrough in cancer treatment can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Cancer blood
GT Biopharma is developing an innovative platform for cancer cell therapy. This is a cutting-edge, yet highly risky, segment of biotech. The chart shows how investor expectations for its unique technology create their own trajectory for the stock, often at odds with overall trends in the healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GT Biopharma develops cancer immunotherapy. This chart shows how its weekly performance, like that of other biotechs, is detached from the market. Share movements are driven by news about clinical trials and regulatory decisions, not macroeconomic data.
Market capitalization of the company, segment and market as a whole
GTBP - Market capitalization of the company GT Biopharma Inc.
GT Biopharma, Inc.'s market capitalization reflects the promise of its TriKE platform for next-generation cancer immunotherapy. The company's valuation hinges on the success of its clinical trials in treating blood cancers. The chart illustrates the high volatility inherent in the early-stage biotech sector.
GTBP - Share of the company's market capitalization GT Biopharma Inc. within the market segment - Cancer blood
GT Biopharma's stake in the oncology sector is a bet on its unique TriKE cell therapy platform. Its market share reflects investors' belief in the potential of this technology to treat difficult-to-treat blood cancers, potentially leading to a breakthrough in immunotherapy.
Market capitalization of the market segment - Cancer blood
This chart shows the total market capitalization of biotech companies developing NK cell-based immunotherapies. GT Biopharma is one of the innovators in this field. The dynamics in the chart reflect how the market views this promising but highly competitive area of cancer treatment.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of a platform for creating "super-fighters" against cancer. GT Biopharma's market capitalization is the valuation of its TriKE technology, which directs immune cells to destroy tumors. The line shows how cutting-edge science shapes its potential value in the global biotechnology industry.
Book value capitalization of the company, segment and market as a whole
GTBP - Book value capitalization of the company GT Biopharma Inc.
The graph below shows GT Biopharma's scientific foundation. Its line represents the value of the intellectual property for its NK cell enhancer platform (TriKE®) for cancer immunotherapy. An increase in the graph indicates progress in clinical trials, the company's primary asset.
GTBP - Share of the company's book capitalization GT Biopharma Inc. within the market segment - Cancer blood
GT Biopharma's tangible assets include its laboratories and, potentially, manufacturing facilities for the innovative TriKE cell therapy platform. The chart reflects its stake in this scientific infrastructure, which is the physical foundation for a new approach to cancer treatment.
Market segment balance sheet capitalization - Cancer blood
Biotechnology is a world of contrasts. The graph shows the enormous factories of pharmaceutical giants. GT Biopharma, a cell therapy developer, has a more streamlined model. Its value lies in its unique scientific platform, not in the scale of its production.
Book value of all companies included in the broad market index - GURU.Markets
GT Biopharma is developing a new generation of immunotherapy for cancer treatment using TriKE technology. The company's assets are not hospitals, but rather a research platform and laboratories where this "three-headed" tumor-fighting weapon is being developed. The chart below shows the financial weight behind this complex biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GT Biopharma Inc.
GT Biopharma is an immuno-oncology company. Its market value is determined by the valuation of its unique platform for developing a new generation of cancer drugs. Investors are buying a stake in a potential medical breakthrough, not in its current tangible assets.
Market to book capitalization ratio in a market segment - Cancer blood
GT Biopharma, Inc. is developing an innovative immunotherapy platform for the treatment of blood cancers. Its value is based on the potential of this technology. This chart shows how its market valuation, reflecting its hopes for a breakthrough in oncology, is many times greater than its current, primarily research, assets.
Market to book capitalization ratio for the market as a whole
GT Biopharma is developing immunotherapy for the treatment of blood cancers. This chart shows how the market values the TriKE® scientific platform and the potential of its future drugs. The high ratio to book value indicates high investor expectations for a breakthrough in cancer treatment.
Debts of the company, segment and market as a whole
GTBP - Company debts GT Biopharma Inc.
GT Biopharma, an immuno-oncology company, is leveraging its financial structure to develop its TriKE platform for treating blood cancers. This chart shows how the company is raising capital to fund preclinical research and early clinical trials, a high-risk but potentially breakthrough activity.
Market segment debts - Cancer blood
GT Biopharma is a biotech company developing the innovative immunotherapy platform TriKE for the treatment of blood cancer. Funding clinical trials is its primary focus. This chart shows how its debt burden reflects the capital requirements to advance this promising technology through the complex and costly development stages.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GT Biopharma Inc.
Taoping Inc. positions itself as a provider of cloud solutions and AI-powered services, primarily for small businesses in China. This chart shows how the company is using capital to develop its technology platforms and expand its customer base in the country's highly competitive and rapidly changing tech market.
Market segment debt to market segment book capitalization - Cancer blood
GT Biopharma is a clinical-stage biotech developing the innovative TriKE platform for treating blood cancer. This chart compares its debt load to the overall market capitalization of the oncology sector. It clearly demonstrates how the company finances its expensive research while being completely dependent on raising capital to bring its therapy to market.
Debt to book value of all companies in the market
GT Biopharma develops innovative immunotherapeutic drugs for the treatment of blood cancers. Biotechnology is one of the most capital-intensive industries. This graph of total market debt helps understand the financial environment in which the company is raising funds to conduct expensive clinical trials of its TriKE platform, which is aimed at fighting cancer.
P/E of the company, segment and market as a whole
P/E - GT Biopharma Inc.
For GT Biopharma, an immuno-oncology company, the P/E ratio is irrelevant. It has no products or revenues. Its valuation on this chart is arbitrary. The company's true value is derived from investors' faith in the potential of its scientific platform to create a new generation of cancer drugs.
P/E of the market segment - Cancer blood
GT Biopharma is developing a new generation of immunotherapeutic drugs for cancer treatment based on its TriKE® platform, which directs natural killer cells (NK cells) to destroy tumors. This chart shows the average valuation for the oncology sector, reflecting investor expectations for advanced immuno-oncology platforms.
P/E of the market as a whole
GT Biopharma is developing the innovative TriKE® immunotherapy platform for cancer treatment. The technology is designed to activate natural killer cells (NK cells) to destroy tumors. This risk appetite chart helps understand how investors evaluate cutting-edge approaches in immuno-oncology.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GT Biopharma Inc.
GT Biopharma is developing innovative NK cell-based immunotherapy for the treatment of blood cancers and solid tumors. This chart demonstrates investor confidence in the breakthrough potential of its TriKE platform. Future revenue depends on the success of clinical trials and partnerships with major pharmaceutical companies.
%20P%2FE%20GT%20Biopharma%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GT-Biopharma-Inc.&v=1772628439130 "Chart of the company's future (projected) P/E GT Biopharma Inc.")
Future (projected) P/E of the market segment - Cancer blood
GT Biopharma is developing the innovative TriKE immunotherapy platform to combat blood cancer. This chart is a barometer of market optimism. It compares investor expectations for its technology's breakthrough with those of dozens of other biotech companies working in the oncology field, demonstrating confidence in its scientific approach.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-blood&v=1772628439149 "Future (projected) P/E graph of the market segment - Cancer blood")
Future (projected) P/E of the market as a whole
GT Biopharma is developing innovative NK cell-based immunotherapy for the treatment of blood cancers and solid tumors. The company's future depends on the results of clinical trials and partnerships. The overall market environment, visible in this chart, influences the willingness of investors and large pharmaceutical companies to invest in advanced but risky biotech platforms.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772628439163 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GT Biopharma Inc.
GT Biopharma is an immuno-oncology company developing cell therapies for cancer treatment. The company's financial activities are focused on conducting expensive clinical trials. This chart shows the company's investment in cutting-edge scientific research, with future returns dependent entirely on positive clinical data and regulatory approval.
Profit of companies in the market segment - Cancer blood
GT Biopharma is developing the innovative TriKE® platform for immunotherapy of oncological diseases, particularly blood cancers. This graph, which reflects the sector's total revenue, demonstrates the potential of these new treatment approaches. GT Biopharma's success in clinical trials could radically change the standard of care and generate significant profits for the entire industry.
Overall market profit
GT Biopharma develops innovative immunotherapies for cancer treatment. Like many early-stage biotech companies, its market cap is based on the potential of its scientific platform. Investors are betting on a future medical breakthrough, and this story is completely independent of the short-term fluctuations in corporate earnings visible on the chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GT Biopharma Inc.
GT Biopharma develops innovative immunotherapeutic drugs for the treatment of blood cancers and solid tumors. This chart displays analyst forecasts based on the potential of its TriKE platform. Revenue expectations are entirely dependent on the success of clinical trials and progress in drug development.
%20profit%20of%20the%20company%20GT%20Biopharma%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GT-Biopharma-Inc.&v=1772628439208 "Graph of future (projected) profit of the company GT Biopharma Inc.")
Future (predicted) profit of companies in the market segment - Cancer blood
GT Biopharma develops innovative immunotherapeutics based on natural killer cells (NK cells) for the treatment of blood cancers. This chart shows future revenue expectations for the entire hematological oncology segment. It allows one to assess the potential of the company's platform against the overall outlook for this competitive biotech field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-blood&v=1772628439217 "Graph of future (predicted) profits of companies in a market segment - Cancer blood")
Future (predicted) profit of the market as a whole
GT Biopharma is developing an innovative immunotherapy platform for the treatment of blood cancer. Like many biotechs, its primary driver is successful clinical trials. However, this graph, reflecting investors' risk appetite, is of paramount importance. Positive economic forecasts facilitate the attraction of the significant capital needed to conduct expensive research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772628439221 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GT Biopharma Inc.
GT Biopharma develops innovative NK cell-based immunotherapeutics for cancer treatment. This metric, which correlates market capitalization with minimal or no revenue, is a clear indicator of expectations. It demonstrates the high valuation that investors place on its scientific platform, betting on a future breakthrough in oncology.
P/S market segment - Cancer blood
GT Biopharma is developing the innovative TriKE® immunotherapeutic platform for the treatment of cancer, particularly hematological malignancies. The technology is aimed at activating natural killer cells. This chart shows the market premium the company is willing to pay for revenue in the advanced oncology sector, reflecting confidence in the scientific potential of GT Biopharma's platform.
P/S of the market as a whole
GT Biopharma develops innovative immuno-oncology drugs based on its TriKE platform for activating natural killer (NK) cells to fight cancer. This chart, showing the average market revenue valuation, highlights that investors value the company based on the potential of its scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GT Biopharma Inc.
GT Biopharma develops innovative immunotherapeutic drugs for cancer treatment. For a company with no current sales, this chart is purely a forward indicator. It shows how investors estimate the potential future revenue from its TriKE platform if clinical trials are successful and the drugs are approved.
%20P%2FS%20GT%20Biopharma%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GT-Biopharma-Inc.&v=1772628439262 "The graph of the company's future (projected) P/S GT Biopharma Inc.")
Future (projected) P/S of the market segment - Cancer blood
GT Biopharma is developing the innovative TriKE immunotherapy platform to combat blood cancers and solid tumors. The chart shows the average estimated future revenue in the blood cancer sector. It helps understand how the market views GT Biopharma's unique scientific approach and its chances of success in this highly competitive area of oncology compared to other immunotherapy technologies.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20blood&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-blood&v=1772628439307 "Future (projected) P/S market segment graph - Cancer blood")
Future (projected) P/S of the market as a whole
GT Biopharma (GTBP) is developing innovative immunotherapy for blood cancer. Their success or failure depends on the results of clinical trials, not the state of the economy. This chart doesn't reflect their potential; their investors follow lab news, not macroeconomic forecasts.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772628439327 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GT Biopharma Inc.
GT Biopharma is at the forefront of cancer immunotherapy. Being in the clinical stage, the company does not yet have revenue from drug sales. This chart reflects revenue generated from strategic alliances and licensing agreements that fund its innovative research into cell therapy for cancer.
Sales of companies in the market segment - Cancer blood
GT Biopharma is developing the innovative TriKE immunotherapy platform for the treatment of oncology. Currently in the clinical stage, the company has no revenue yet. Its future revenue structure will depend on which of its candidates, targeting various types of blood cancer, achieves commercial success first.
Overall market sales
GT Biopharma, Inc. develops immunotherapeutic drugs for the treatment of blood cancers. The company's activities are not driven by consumer trends, but depend on funding and partnerships. The overall economic environment, shown in this chart, influences investor risk appetite and the strategic budgets of large pharmaceutical companies that may partner with GT Biopharma.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GT Biopharma Inc.
GT Biopharma is an immuno-oncology company developing cell therapies for the treatment of blood cancers. Its future revenue is entirely dependent on the success of clinical trials and subsequent drug approvals. This chart reflects analysts' long-term expectations regarding the breakthrough potential of its TriKE platform.
%20sales%20of%20the%20company%20GT%20Biopharma%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GT-Biopharma-Inc.&v=1772628439427 "Schedule of future (projected) sales of the company GT Biopharma Inc.")
Future (projected) sales of companies in the market segment - Cancer blood
GT Biopharma is developing innovative immunotherapy based on NK (natural killer) cells for the treatment of blood cancers and solid tumors. This chart shows the outlook for the blood cancer sector. It reflects the high scientific interest in cell therapy, which is important for attracting investment and partnerships for GT Biopharma's TriKE platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-blood&v=1772628439429 "Schedule of future (projected) sales of companies in the market segment - Cancer blood")
Future (projected) sales of the market as a whole
This chart shows investment appetite in biotech, which is critical for GT Biopharma. The company, which is developing immunotherapy for blood cancer, is dependent on funding. Positive economic forecasts are stimulating the influx of venture capital needed to advance these expensive developments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772628439431 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GT Biopharma Inc.
GT Biopharma is developing a new generation of NK cell-based immunotherapeutics for cancer treatment. This chart shows the company's financial performance during the intensive research phase. Profitability is a long-term goal, dependent on clinical trial results and potential partnerships with major pharmaceutical companies.
Market segment marginality - Cancer blood
GT Biopharma develops innovative immuno-oncology drugs based on its TriKE® platform for the treatment of blood cancers. The company's profitability depends on the success of its clinical programs and partnerships. This chart shows the average profitability in the pharmaceutical industry. It allows one to assess the potential for GT Biopharma's technology to be a breakthrough in cancer treatment.
Market marginality as a whole
GT Biopharma develops innovative immunotherapeutic drugs for the treatment of blood cancer. Like many biotech companies, it relies on investment to conduct clinical trials. This chart shows the overall market willingness to invest in risky but potentially breakthrough scientific projects, which directly impacts GT Biopharma's ability to continue operations.
Employees in the company, segment and market as a whole
Number of employees in the company GT Biopharma Inc.
GT Biopharma develops innovative immunotherapeutic drugs for the treatment of blood cancers. This chart shows the size of the scientific and clinical teams advancing their unique technology. A small team is typical for a biotech startup focused on research. Growth will mean progress in clinical programs and closer market penetration.
Share of the company's employees GT Biopharma Inc. within the market segment - Cancer blood
GT Biopharma is developing TriKE, an innovative cancer immunotherapy platform that directs natural killer cells to destroy tumor cells. This chart shows the percentage of all immuno-oncology researchers the company attracts. This indicates its cutting-edge scientific approach and potential for creating next-generation blood cancer treatments.
Number of employees in the market segment - Cancer blood
GT Biopharma is developing innovative immunotherapeutics based on its TriKE® platform for the treatment of oncological diseases, particularly blood cancers. This chart, showing employment in the hematological oncology sector, is important. The growing number of researchers indicates rapid progress in this field and the race to create more effective cell therapies.
Number of employees in the market as a whole
GT Biopharma develops innovative immunotherapy methods for cancer treatment. Funding for such cutting-edge research is directly dependent on the state of the economy. This chart, showing employment growth, indicates a healthy investment environment, where venture capital funds and large pharmaceutical companies have the resources to support biotech companies working at the forefront of science.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GT Biopharma Inc. (GTBP)
GT Biopharma is an immuno-oncology company developing a cell therapy (CAR-NK) for the treatment of blood cancer. As with most biotech companies, this metric reflects not current productivity but the market's confidence in their science. A small staff of scientists is working with intellectual property that, if successful, could be worth billions.
%20of%20the%20company%20GT%20Biopharma%20Inc.%20(GTBP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GT-Biopharma-Inc.-GTBP&v=1772628439601 "Chart of market capitalization per employee (in thousands of dollars) of the company GT Biopharma Inc. (GTBP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer blood
GT Biopharma develops innovative immunotherapy methods for cancer treatment. Like many biotech companies, its value is determined not by current sales, but by the potential of its scientific developments. This metric clearly illustrates that its market capitalization is based on a small group of highly qualified researchers, unlike labor-intensive sectors of the economy.
%20by%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-blood&v=1772628439609 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer blood")
Market capitalization per employee (in thousands of dollars) for the overall market
GT Biopharma develops innovative immunotherapeutic drugs for cancer treatment based on NK cells. The company's market capitalization reflects the potential of its scientific platform. This metric demonstrates the enormous value the market places on the intellectual property generated by a small but highly specialized team of researchers.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772628439610 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GT Biopharma Inc. (GTBP)
GT Biopharma is an immuno-oncology company developing the TriKE platform for activating NK (natural killer) cells to fight blood cancers. This is cutting-edge science. This chart reflects the "cost of R&D": it shows how much the company spends (negative profit) on each scientist trying to create this next-generation therapy.
%20Chart%20GT%20Biopharma%20Inc.%20(GTBP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GT-Biopharma-Inc.-GTBP&v=1772628439623 "Company Profit Per Employee (in thousands of dollars) Chart GT Biopharma Inc. (GTBP)")
Profit per employee (in thousands of dollars) in the market segment - Cancer blood
GT Biopharma develops immunotherapeutic drugs for the treatment of blood cancer. Since the company is in clinical trials, traditional profits may not be possible. The metric on the chart rather reflects capital management efficiency—how wisely the company spends its research investments while maintaining a relatively small but highly qualified staff.
%20in%20the%20market%20segment%20-%20Cancer%20blood&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-blood&v=1772628439636 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer blood")
Profit per employee (in thousands of dollars) for the market as a whole
GT Biopharma (GTBP) is a biopharmaceutical company focused on immuno-oncology. They are developing the TriKE platform for activating NK (natural killer) cells to fight cancer. They are an R&D company. This metric reflects not current revenue, but rather the investment in research and development personnel who are creating a cutting-edge technology platform for future drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772628439648 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GT Biopharma Inc. (GTBP)
GT Biopharma develops innovative immunotherapy treatments for cancer. For a company in clinical trials, this graph is an indicator of potential. A lack of revenue now could be followed by a sharp increase after the drug's approval, reflecting the value of the scientific team's work.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GT-Biopharma-Inc.-GTBP&v=1772628439672 "Sales chart per company employee GT Biopharma Inc. (GTBP)")
Sales per employee in the market segment - Cancer blood
GT Biopharma is an immuno-oncology company developing the TriKE platform for activating NK (natural killer) cells against blood cancers. This is an R&D business. This graph shows that the productivity of their scientific team is not measured by current sales (there are none). Efficiency here is the speed at which candidates move toward FDA approval.
Sales per employee for the market as a whole
Fluence Energy (FLNC) is a pioneer in large-scale energy storage systems needed for grid stabilization and renewable energy integration. It's a project-based business, with each contract representing a large installation. This chart reflects how effectively the company manages these complex projects. This growth indicates that Fluence is successfully moving from the R&D phase to commercial deployment.
Short shares by company, segment and market as a whole
Shares shorted by company GT Biopharma Inc. (GTBP)
GT Biopharma (GTBP) is also working in the field of immuno-oncology, developing a therapy for blood cancer. This chart tracks bearish bets. Like SLRX, the shorts reflect binary risk: investors are betting that the company's technology will prove ineffective or unsafe in human trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GT-Biopharma-Inc.-GTBP&v=1772628439711 "Short Shares Chart for the Company GT Biopharma Inc. (GTBP)")
Shares shorted by market segment - Cancer blood
GT Biopharma (GTBP) is developing an innovative immunotherapy (TriKE) for the treatment of blood cancer. The chart below shows the aggregate short position in the oncology biotech sector. It shows how many investors are skeptical of new cell therapy platforms, fearing late-stage failures.
Shares shorted by the overall market
GT Biopharma is developing a platform (TriKE) for immunotherapy of blood cancer. This is cutting-edge, but very early technology. This chart measures overall fear. When investors are afraid, they are unwilling to bet on fundamental R&D. They sell off GTBP shares, fearing the company will run out of money before the technology is proven.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GT Biopharma Inc. (GTBP)
This oscillator for GT Biopharma is an indicator of faith in their TriKE platform. The company is developing a technology that targets NK (natural killer) cells against blood cancers. "Overheating" (above 70) occurs due to positive Phase 1/2 data. High competition in cell therapy and the risk of failure in late phases lead to "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GT-Biopharma-Inc.-GTBP&v=1772628439719 "RSI 14 indicator chart for the company's stock GT Biopharma Inc. (GTBP)")
RSI 14 Market Segment - Cancer blood
GT Biopharma is a biopharmaceutical company developing the TriKE® immunotherapy platform. This technology directs NK (natural killer) cells to destroy cancer cells in the blood (leukemia, lymphoma). This chart reflects the overall sentiment in the oncology sector and helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
GT Biopharma (GTBP) is developing immunotherapy for cancer treatment. Like most clinical-stage biotechs, access to capital is vital for GTBP. This chart measures the market's "temperature," showing investors' risk appetite. During periods of euphoria (overbought), funding for innovation is readily available. During periods of panic (oversold), investors avoid stocks of companies that don't yet have stable revenues.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GTBP (GT Biopharma Inc.)
GT Biopharma is a biotech company developing the TriKE immuno-oncology platform, which directs NK (natural killer) cells to attack cancer cells (e.g., leukemia). This chart shows the speculative average 12-month price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GTBP-GT-Biopharma-Inc.&v=1772628439724 "A chart showing analyst consensus forecasts for the expected stock price. GTBP (GT Biopharma Inc.)")
The difference between the consensus estimate and the actual stock price GTBP (GT Biopharma Inc.)
GT Biopharma is an immuno-oncology company developing the TriKE platform—triple antibodies that target natural killer (NK) cells against blood cancers. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GTBP-GT-Biopharma-Inc.&v=1772628439728 "A chart showing the difference between the consensus forecast and the actual stock price. GTBP (GT Biopharma Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer blood
GT Biopharma is an R&D biotech company developing immune system "guidance" (TriKE) for the treatment of blood cancer. This is high-risk R&D. This chart reflects analysts' overall expectations for the entire blood cancer sector. It shows whether experts believe in the success of junior R&D platforms in oncology.
Analysts' consensus forecast for the overall market share price
GT Biopharma is a biotech company developing an immunotherapy platform (TriKE) that directs NK (killer) cells to destroy blood cancer cells. This chart shows the overall risk appetite in the market. For GTBP, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GT Biopharma Inc.
GT Biopharma is a bispecific biotech. Their signature drug is TriKE, a three-part smart molecule that (they claim) binds NK cells (immunity) to cancer cells (blood cancer) more powerfully than competitors. This graph is a pure indicator of their R&D, reflecting their (very risky) progress in clinical trials.
AKIMA Market Segment Index - Cancer blood
GT Biopharma is developing TriKE immunotherapy for the treatment of blood cancers. This technology trains a patient's own immune cells (NK cells) to recognize and attack tumors. This graph compares their composite index to the sector, showing how their cutting-edge approach to immuno-oncology outperforms the competition.
The AKIM Index for the overall market
GT Biopharma is an immuno-oncology company using TriKE (NK cell) technology to treat blood cancers and solid tumors. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop important for funding this platform.
